Compare Aventis Pharma with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs DR. REDDYS LAB - Comparison Results

SANOFI INDIA     Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA DR. REDDYS LAB SANOFI INDIA/
DR. REDDYS LAB
 
P/E (TTM) x 36.1 21.5 168.0% View Chart
P/BV x 6.3 3.2 196.7% View Chart
Dividend Yield % 1.4 0.7 187.5%  

Financials

 SANOFI INDIA   DR. REDDYS LAB
EQUITY SHARE DATA
    SANOFI INDIA
Dec-18
DR. REDDYS LAB
Mar-19
SANOFI INDIA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs6,8402,875 237.9%   
Low Rs4,6301,888 245.2%   
Sales per share (Unadj.) Rs1,203.1930.2 129.3%  
Earnings per share (Unadj.) Rs165.3117.4 140.7%  
Cash flow per share (Unadj.) Rs209.9185.8 113.0%  
Dividends per share (Unadj.) Rs84.0020.00 420.0%  
Dividend yield (eoy) %1.50.8 174.4%  
Book value per share (Unadj.) Rs963.6844.4 114.1%  
Shares outstanding (eoy) m23.03166.07 13.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.82.6 186.2%   
Avg P/E ratio x34.720.3 171.1%  
P/CF ratio (eoy) x27.312.8 213.2%  
Price / Book Value ratio x6.02.8 211.0%  
Dividend payout %50.817.0 298.4%   
Avg Mkt Cap Rs m132,078395,496 33.4%   
No. of employees `0003.322.0 15.0%   
Total wages/salary Rs m4,06833,562 12.1%   
Avg. sales/employee Rs Th8,393.87,032.8 119.4%   
Avg. wages/employee Rs Th1,232.41,527.9 80.7%   
Avg. net profit/employee Rs Th1,153.0887.7 129.9%   
INCOME DATA
Net Sales Rs m27,708154,482 17.9%  
Other income Rs m8973,375 26.6%   
Total revenues Rs m28,605157,857 18.1%   
Gross profit Rs m6,23531,782 19.6%  
Depreciation Rs m1,02711,348 9.1%   
Interest Rs m7889 0.8%   
Profit before tax Rs m6,09822,920 26.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,2923,858 59.4%   
Profit after tax Rs m3,80619,500 19.5%  
Gross profit margin %22.520.6 109.4%  
Effective tax rate %37.616.8 223.3%   
Net profit margin %13.712.6 108.8%  
BALANCE SHEET DATA
Current assets Rs m15,922111,101 14.3%   
Current liabilities Rs m6,23558,973 10.6%   
Net working cap to sales %35.033.7 103.6%  
Current ratio x2.61.9 135.5%  
Inventory Days Days6479 80.2%  
Debtors Days Days2194 22.2%  
Net fixed assets Rs m7,539101,245 7.4%   
Share capital Rs m230830 27.7%   
"Free" reserves Rs m21,962139,406 15.8%   
Net worth Rs m22,192140,236 15.8%   
Long term debt Rs m022,000 0.0%   
Total assets Rs m29,839224,656 13.3%  
Interest coverage x872.126.8 3,256.5%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x0.90.7 135.0%   
Return on assets %12.89.1 140.8%  
Return on equity %17.213.9 123.3%  
Return on capital %27.514.9 184.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m7,58788,673 8.6%   
Fx outflow Rs m7,14519,104 37.4%   
Net fx Rs m44269,569 0.6%   
CASH FLOW
From Operations Rs m3,73928,704 13.0%  
From Investments Rs m-731-7,727 9.5%  
From Financial Activity Rs m-1,972-21,326 9.2%  
Net Cashflow Rs m1,036-314 -329.9%  

Share Holding

Indian Promoters % 0.0 25.5 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 5.4 266.7%  
FIIs % 14.6 35.3 41.4%  
ADR/GDR % 0.0 18.5 -  
Free float % 10.5 15.3 68.6%  
Shareholders   15,184 75,885 20.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   ORCHID PHARMA LTD  CIPLA  ASTRAZENECA PHARMA  SUVEN LIFESCIENCES  STERLING BIOTECH  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Oct 18, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS